Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 December 2007

Modified release formulation in immunotherapy – the tacrolimus case

N. Undre

Ann Transplant 2008; 13(1): 32-32 :: ID: 880186

Abstract

Tacrolimus, is a CNI marketed under the trade name Prograf[sup]®[/sup]; oral Prograf capsules are administered as a twice-daily dosing regimen. Poor compliance with dosing has been shown to be one of the factors associated with the incidence of transplant rejection and late graft loss and the likelihood for adherence is better with a once daily dosing regimen compared to that with twice daily dosing regimen. Advagraf has been developed as a once daily formulation of tacrolimus aimed at improving compliance with dosing and thereby decreasing the risk of late graft rejection and loss. Pharmacokinetics of Advagraf have been evaluated in stable adult kidney, liver and heart transplant recipients as well as de novo liver and kidney transplant recipients. In stable patients following conversion from Prograf to Advagraf on a 1:1 (mg:mg) total daily dose, systemic exposure to tacrolimus over 24 hour (AUC0-24) was similar. In de novo kidney and liver transplant patients AUC[sub]0-24[/sub] of tacrolimus for Advagraf on Day 1 was 30% and 50% lower respectively, when compared with that for Prograf at equivalent doses. By Day 4, systemic exposure is similar with both formulations. Efficacy and safety profile of Advagraf was comparable to Prograf with a patient follow up of up to 3 years. There was good correlation between AUC[sub]0-24[/sub] and trough level (C[sub]24[/sub]) of tacrolimus for Advagraf and the relationship between these two parameters is similar to that for Prograf, thus, therapy for both formulations can be optimised using the same therapeutic monitoring concept.

Keywords: Tacrolimus, Liver, Kidney Transplant

0 Comments

In Press

04 Aug 2022 : Original article  

Long-Term Patency of All-in-One Sleeve Patch Graft Venoplasty in 16 Patients Who Underwent Living Donor Liv...

Ann Transplant In Press; DOI: 10.12659/AOT.936888  

22 Jul 2022 : Original article  

Diagnostic Role of Tumor Markers for Hepatocellular Carcinoma in Liver Transplantation Candidates: An Analy...

Ann Transplant In Press; DOI: 10.12659/AOT.936937  

22 Jul 2022 : Original article  

Development of a Novel Model for Predicting Postoperative Short-Term Outcome in Patients with Hepatitis B-R...

Ann Transplant In Press; DOI: 10.12659/AOT.936732  

22 Jul 2022 : Original article  

Leucine-Rich Alpha-2-Glycoprotein (LRG-1) as a Potential Kidney Injury Marker in Kidney Transplant Recipients

Ann Transplant In Press; DOI: 10.12659/AOT.936751  

Most Viewed Current Articles

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

24 Jul 2020 : Review article  

Kidney Transplantation in the Times of COVID-19 – A Literature Review

DOI :10.12659/AOT.925755

Ann Transplant 2020; 25:e925755

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358